...
首页> 外文期刊>Cardiology >The CHA(2)DS(2)-VASc Score and Its Association with Long-Term Outcome in a Cardiac Resynchronization Therapy Population
【24h】

The CHA(2)DS(2)-VASc Score and Its Association with Long-Term Outcome in a Cardiac Resynchronization Therapy Population

机译:CHA(2)DS(2)-vasc评分及其在心脏重新同步治疗人群中与长期结果的关联

获取原文
获取原文并翻译 | 示例

摘要

Background: Cardiac resynchronization therapy (CRT) is commonly used in patients with heart failure and left ventricular dyssynchrony. Several scoring systems have been tested in order to predict long-term outcome. Although intended for use in patients with atrial fibrillation, we sought to assess the performance of the CHA(2)DS(2)-VASc score in a CRT population. Methods: Data on 796 consecutive CRT patients were retrospectively gathered from hospital records and healthcare registries. CHA(2)DS(2)-VASc scores were calculated, as well as other stratification scores for comparison. The outcomes were crude mortality, time to first heart failure hospitalization, and a composite of the 2. CHA(2)DS(2)-VASc score was evaluated against the end points with survival analyses and compared to other risk stratification scores. Results: The CHA(2)DS(2)-VASc score was significantly correlated with both outcomes in univariable and multivariable analysis adjusting for other known predictors of CRT outcome (unadjusted HR 1.28, 95% CI 1.21-1.36 and HR 1.19, 95% CI 1.13-1.25 for the mortality and heart failure hospitalization end points, respectively). Its performance compared well to other validated scores for the mortality end point (Harrell's C: 0.61, range for other scoring systems: 0.57-0.65), as well as the heart failure hospitalization end point (Harrell's C: 0.57, range of other scoring systems: 0.58-0.62). It correlated to 5- and 10-year survival with an area under the curve of 0.63 and 0.73, respectively. Conclusion: When tested for association with outcome in a CRT population, the CHA(2)DS(2)-VASc score correlates to increased mortality and risk of heart failure hospitalization. It performs similarly to CRT-specific scores. However, the results of this study indicate that all tested scores should be used with caution in CRT patients.
机译:背景:心脏再同步治疗(CRT)通常用于心力衰竭和左心室不同步的患者。为了预测长期结果,已经测试了几种评分系统。尽管旨在用于房颤患者,但我们试图在CRT人群中评估CHA(2)DS(2)-VASc评分的表现。方法:从医院记录和医疗登记处回顾性收集796例连续CRT患者的资料。计算CHA(2)DS(2)-VASc评分,以及其他分层评分进行比较。结果是粗死亡率、首次心衰住院时间和2项指标的综合。CHA(2)DS(2)-VASc评分根据生存分析终点进行评估,并与其他风险分层评分进行比较。结果:在单变量和多变量分析中,校正CRT结果的其他已知预测因素(死亡率和心力衰竭住院终点的未调整HR1.28,95%可信区间1.21-1.36和HR1.19,95%可信区间1.13-1.25),CHA(2)DS(2)-VASc评分与两种结果显著相关。其表现与死亡率终点的其他验证分数(哈雷尔C:0.61,其他评分系统的范围:0.57-0.65)以及心力衰竭住院终点(哈雷尔C:0.57,其他评分系统的范围:0.58-0.62)相比良好。它与5年和10年生存率相关,曲线下面积分别为0.63和0.73。结论:当在CRT人群中检测与预后的相关性时,CHA(2)DS(2)-VASc评分与死亡率增加和心力衰竭住院风险相关。它的表现类似于CRT的特定分数。然而,这项研究的结果表明,CRT患者应谨慎使用所有测试分数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号